What flexibility does inhaled insulin actually give kids?
Inhaled insulin is a needle-free option that works faster than traditional rapid-acting injections, which can make mealtime dosing more convenient and less intimidating for children. In the INHALE-1 trial, kids using inhaled technosphere insulin reported significantly higher treatment satisfaction than those using injections (p=0.004) [2]. This satisfaction likely stems from avoiding multiple daily injections, which can be a major burden for young patients. The ultra-rapid action also means it can be taken right at the start of a meal, offering more flexibility in timing compared to injections that need to be given 15-30 minutes before eating [5].
Are there new safety concerns, especially for lungs?
The main new safety concern is lung function, but the evidence so far is reassuring. In the 26-week INHALE-1 trial, there was no significant difference in lung function (measured by forced expiratory volume in 1 second, or FEV1) between inhaled insulin and injection groups [2]. A 52-week extension study also found no serious or unexpected pulmonary adverse events, and the change in FEV1 after stopping inhaled insulin was negligible (-0.5% predicted) [1]. However, these studies are relatively short-term, and long-term effects on lungs are not yet known. The extension study did note a slight deterioration in HbA1c over time (mean increase of 0.38% from 26 to 52 weeks), which is a safety concern in terms of glucose control, not lung health [1].
How do the benefits and risks balance out for different kids?
The balance depends on the child's baseline control and preferences. In a subgroup analysis of kids with baseline HbA1c ≤9.5%, inhaled insulin was non-inferior to injections (difference of 0.11%, within the 0.4% margin), meaning it worked just as well for those with moderate control [3]. But in the overall trial, which included kids with higher HbA1c, inhaled insulin did not meet the non-inferiority criteria, with a mean HbA1c increase of 0.18% more than injections [2]. This suggests that for kids with very high blood sugars, injections might be more effective. Additionally, inhaled insulin was associated with less weight gain (p=0.009) [2], which could be a benefit for some. Ultimately, the choice should be individualized, considering the child's comfort with needles, their ability to manage mealtime dosing, and their glycemic targets.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2025 to 2026, 5 from 2024 or later, 3 in Q1 journals — selected as the most relevant from 5 studies that passed quality screening, drawn from 67 papers retrieved from a database of over 500 million.
Sources used in this answer
Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study.
In a 52-week extension of the INHALE-1 trial, inhaled technosphere insulin showed no serious pulmonary adverse events, but HbA1c increased by 0.38% from 26 to 52 weeks, indicating a slight decline in glucose control.
INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes
In the 26-week INHALE-1 randomized controlled trial of 230 children, inhaled insulin did not meet non-inferiority for HbA1c (difference 0.18%), but was safe with no lung function changes, and was associated with higher treatment satisfaction and less weight gain.
1741-P: Efficacy and Safety of Inhaled Technosphere Insulin (TI) vs. Rapid-Acting Analog in Youth with HbA1c ≤9.5%: Subgroup Analysis from INHALE-1
In a subgroup of youth with baseline HbA1c ≤9.5% from INHALE-1, inhaled insulin was non-inferior to rapid-acting analog (difference 0.11%), with stable pulmonary function and similar CGM metrics.
833-P: Efficacy and Safety of Prandial Technosphere Inhaled Insulin (Afrezza) Compared with Placebo in Adult Individuals with T2DM—Results from a Phase III Clinical Trial from India
In a phase III trial in Indian adults with type 2 diabetes, inhaled technosphere insulin significantly reduced HbA1c by 0.62% vs 0.20% for placebo, with no significant lung function differences.
Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes
A review article highlights the potential of inhaled technosphere insulin to improve glycemic management and adherence in pediatric type 1 diabetes, but notes challenges including the need for long-term safety data.